Please login to the form below

Not currently logged in
Email:
Password:

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has been approved by the European Commission (EC) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease

Latest news

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...